- Home
- PHAT vs NGL Comparison
PHAT vs NGL Comparison
Compare PHAT & NGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- NGL
- Stock Information
- Founded
- PHAT 2018
- NGL 1940
- Country
- PHAT United States
- NGL United States
- Employees
- PHAT N/A
- NGL N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- NGL Natural Gas Distribution
- Sector
- PHAT Health Care
- NGL Utilities
- Exchange
- PHAT Nasdaq
- NGL Nasdaq
- Market Cap
- PHAT 820.8M
- NGL 751.7M
- IPO Year
- PHAT 2019
- NGL 2011
- Fundamental
- Price
- PHAT $11.66
- NGL $5.80
- Analyst Decision
- PHAT Strong Buy
- NGL
- Analyst Count
- PHAT 5
- NGL 0
- Target Price
- PHAT $16.40
- NGL N/A
- AVG Volume (30 Days)
- PHAT 1.1M
- NGL 733.7K
- Earning Date
- PHAT 11-06-2025
- NGL 11-11-2025
- Dividend Yield
- PHAT N/A
- NGL N/A
- EPS Growth
- PHAT N/A
- NGL N/A
- EPS
- PHAT N/A
- NGL N/A
- Revenue
- PHAT $114,039,000.00
- NGL $3,332,108,000.00
- Revenue This Year
- PHAT $207.52
- NGL N/A
- Revenue Next Year
- PHAT $96.46
- NGL N/A
- P/E Ratio
- PHAT N/A
- NGL N/A
- Revenue Growth
- PHAT 1049.82
- NGL 1.08
- 52 Week Low
- PHAT $2.21
- NGL $2.64
- 52 Week High
- PHAT $19.71
- NGL $5.99
- Technical
- Relative Strength Index (RSI)
- PHAT 54.88
- NGL 76.87
- Support Level
- PHAT $11.89
- NGL $5.01
- Resistance Level
- PHAT $13.00
- NGL $5.59
- Average True Range (ATR)
- PHAT 0.71
- NGL 0.20
- MACD
- PHAT -0.11
- NGL 0.02
- Stochastic Oscillator
- PHAT 26.57
- NGL 84.55
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.